POLYMOLECULAR PHYTOMEDICINES FOR CANCER

The Current Cancer Treatments

Cancer is a highly complex disease with multiple mutations and various molecular targets, making it a challenge to treat effectively. Unfortunately, many current therapies fail to address important aspects of the disease, such as tumor metabolism regulation and immune system enhancement. As a result, these therapies often induce resistance, require dose increases, and have high toxicity and collateral effects such as mucositis or cardiopathy.

Additionally, their high cost and limited access mean that many patients are unable to benefit from them.

Problem

Cancer causes about 9.6 million deaths worldwide. The current therapies are expensive, have limited access and present problems such as resistance, high toxicity and severe side effects as drug resistance, high toxicity and serious side effects .

Solution

Polymolecular drugs based on natural extracts that offer multiple beneﬁts in the treatment of cancer, including reduction of inﬂammation, modulation of energetic metabolism and activation of the immune system.

Science, technology and natural resourcesv improving cancer recovery

With over 18 years of research experience, our team has created medicines acting as an endogenous vaccine.

Our medicines reduce recovery time and improve the well-being of cancer patients. We offer new hope for a full recovery and a better quality of life.

Dreembio medicines

Regulating tumor energy metabolism.

Activating antitumor immune response.

Improving the tumor microenvironment. Acting with very low toxicity and no side effects.

Being a great adjuvant to chemotherapy and/or radiotherapy in cancer.

Proved Technology for Phytomedicines

A patented proved track record

With 12 patents and research spanning over 18 years, the medicines developed by Dreembio have shown, over multiple studies and trials a remarkable reduction in cancer tumor size by up to 75% and 3.7 times in metastasis for breast cancer, melanoma, and leukemia in mice models. US 9M in grants and several awards.

Dreembio initial products

CS-RadioCare (2023) Cream for radiodermatitis: Reduces inflammation generated by gamma-radiation.
CS-DiviPet (2023) Supplement for Veterinary cancer control.
CS-DiviCare (2023) Antioxidant, activator of innate immune responses. Reduce viral replication.
CS-ImmunoBreast (2025) For breast cancer treatment
PA-Anamu (2026) Gastric-pancreas-leukemia treatment .

DreemBio’s business advantages

Has received grants from World Bank USD 5M and from local government USD 3M.

Permit granted from Ministry of the Environment for next 30 years to commercialize biodiversity- derived products.

DreemBio products can be used in several types of cancer

The best scientific team expert in polymolecular medicines in cancer.

Drug approval faster (rare diseases)

The Startup is one of the leaders in The Latin American startups ecosystem getting support through well-known accelerator programs such as Méntor from Universidad Nacional de Colombia

Committed to fair trade and gender equity

A great worldwide opportunity, with unique advantages

Oncology 286.04 Billion 8.2%.
Cancer drugs 147.6 Billion (8.4% CAGR)* (8.4% CAGR)*.
Billion (8.4% CAGR)*
Growth: Europe 65.9 Billion – CAGR
7.4% – U.S. 6.2% PLANT-BASED MEDICINES 8% – 5.4% CAGR
Plant-derived medicines 8% – 5.2 Billion growing by 8.3% CAGR
Billion growing by 8.3%.
Breast cancer only (20%) 1.04B
Plant based market 8% 11.78B

A team of excellence

Susana Fiorentino

Scientific Director, Founder.

PhD – Titular II Professor. Immunology and Oncology. Leader of the scientific team with more than 29 years of experience in R&D.

Colombian-French nationality

Adolfo Nemirosky

International Business and Associations

More than 25 years of experience in the creation of technology-based companies, serial entrepreneur. Founder of Simply Agave, Stelagenomics, Orfanbio Clearwater Network, and FlowStorm.

Francisco Barnier

Financial Advisor

Senior C-level executive, with solid experience in corporate finance, international business development, and portfolio management in commercial and investment banking and real sectors, as well as advising a government seed capital fund.